Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

HUNK Phosphorylates Rubicon to Support Autophagy.

Zambrano JN, Eblen ST, Abt M, Rhett JM, Muise-Helmericks R, Yeh ES.

Int J Mol Sci. 2019 Nov 19;20(22). pii: E5813. doi: 10.3390/ijms20225813.

2.

HUNK phosphorylates EGFR to regulate breast cancer metastasis.

Williams CB, Phelps-Polirer K, Dingle IP, Williams CJ, Rhett MJ, Eblen ST, Armeson K, Hill EG, Yeh ES.

Oncogene. 2019 Oct 9. doi: 10.1038/s41388-019-1046-5. [Epub ahead of print]

PMID:
31597954
3.

Targeting Chromatin Remodeling for Cancer Therapy.

Kaur J, Daoud A, Eblen ST.

Curr Mol Pharmacol. 2019;12(3):215-229. doi: 10.2174/1874467212666190215112915.

PMID:
30767757
4.

Staurosporine, an inhibitor of hormonally up-regulated neu-associated kinase.

Zambrano JN, Williams CJ, Williams CB, Hedgepeth L, Burger P, Dilday T, Eblen ST, Armeson K, Hill EG, Yeh ES.

Oncotarget. 2018 Nov 13;9(89):35962-35973. doi: 10.18632/oncotarget.26311. eCollection 2018 Nov 13.

5.

Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes.

Eblen ST.

Adv Cancer Res. 2018;138:99-142. doi: 10.1016/bs.acr.2018.02.004. Epub 2018 Mar 2. Review.

6.

MOAP-1, UBR5 and cisplatin resistance in ovarian cancer.

Eblen ST, Bradley A.

Transl Cancer Res. 2017 Feb;6(Suppl 1):S18-S21. doi: 10.21037/tcr.2017.02.01. No abstract available.

7.

Rapid Renal Regulation of Peroxisome Proliferator-activated Receptor γ Coactivator-1α by Extracellular Signal-Regulated Kinase 1/2 in Physiological and Pathological Conditions.

Collier JB, Whitaker RM, Eblen ST, Schnellmann RG.

J Biol Chem. 2016 Dec 23;291(52):26850-26859. doi: 10.1074/jbc.M116.754762. Epub 2016 Nov 14.

8.

EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.

Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood AK, Landen CN Jr, Eblen ST.

Carcinogenesis. 2014 May;35(5):1100-9. doi: 10.1093/carcin/bgt489. Epub 2013 Dec 30.

9.

Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells.

Ali MW, Cacan E, Liu Y, Pierce JY, Creasman WT, Murph MM, Govindarajan R, Eblen ST, Greer SF, Hooks SB.

PLoS One. 2013;8(3):e60185. doi: 10.1371/journal.pone.0060185. Epub 2013 Mar 22.

10.

Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion.

Liu Y, Conaway L, Rutherford Bethard J, Al-Ayoubi AM, Thompson Bradley A, Zheng H, Weed SA, Eblen ST.

Nucleic Acids Res. 2013 May;41(9):4949-62. doi: 10.1093/nar/gkt170. Epub 2013 Mar 21.

11.

EGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK.

Mueller KL, Powell K, Madden JM, Eblen ST, Boerner JL.

Transl Oncol. 2012 Oct;5(5):327-34. Epub 2012 Oct 1.

12.

Oncogenic K-Ras regulates bioactive sphingolipids in a sphingosine kinase 1-dependent manner.

Gault CR, Eblen ST, Neumann CA, Hannun YA, Obeid LM.

J Biol Chem. 2012 Sep 14;287(38):31794-803. doi: 10.1074/jbc.M112.385765. Epub 2012 Jul 24.

13.

Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion.

Al-Ayoubi AM, Zheng H, Liu Y, Bai T, Eblen ST.

Mol Cell Biol. 2012 Jul;32(14):2880-93. doi: 10.1128/MCB.06327-11. Epub 2012 May 21.

14.

Regulation of chemoresistance via alternative messenger RNA splicing.

Eblen ST.

Biochem Pharmacol. 2012 Apr 15;83(8):1063-72. doi: 10.1016/j.bcp.2011.12.041. Epub 2012 Jan 8. Review.

15.

Identification of phosphorylation sites on the E3 ubiquitin ligase UBR5/EDD.

Bethard JR, Zheng H, Roberts L, Eblen ST.

J Proteomics. 2011 Dec 21;75(2):603-9. doi: 10.1016/j.jprot.2011.08.023. Epub 2011 Sep 6.

PMID:
21924388
16.

Identification of novel substrates of MAP Kinase cascades using bioengineered kinases that uniquely utilize analogs of ATP to phosphorylate substrates.

Zheng H, Al-Ayoubi A, Eblen ST.

Methods Mol Biol. 2010;661:167-83. doi: 10.1007/978-1-60761-795-2_10.

PMID:
20811983
17.

Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.

Li Q, Wu J, Zheng H, Liu K, Guo TL, Liu Y, Eblen ST, Grant S, Zhang S.

Bioorg Med Chem Lett. 2010 Aug 1;20(15):4526-30. doi: 10.1016/j.bmcl.2010.06.030. Epub 2010 Jun 8.

PMID:
20580230
18.

Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.

Li Q, Al-Ayoubi A, Guo T, Zheng H, Sarkar A, Nguyen T, Eblen ST, Grant S, Kellogg GE, Zhang S.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6042-6. doi: 10.1016/j.bmcl.2009.09.057. Epub 2009 Sep 18.

19.

ERK activation and nuclear signaling induced by the loss of cell/matrix adhesion stimulates anchorage-independent growth of ovarian cancer cells.

Al-Ayoubi A, Tarcsafalvi A, Zheng H, Sakati W, Eblen ST.

J Cell Biochem. 2008 Oct 15;105(3):875-84. doi: 10.1002/jcb.21889.

PMID:
18726893
20.

MEK1 activation by PAK: a novel mechanism.

Park ER, Eblen ST, Catling AD.

Cell Signal. 2007 Jul;19(7):1488-96. Epub 2007 Jan 24.

21.

Using genetically engineered kinases to screen for novel protein kinase substrates: phosphorylation of substrates in cell lysates with exogenous kinase.

Eblen ST, Kumar NV, Weber MJ.

CSH Protoc. 2007 Apr 1;2007:pdb.prot4639. doi: 10.1101/pdb.prot4639.

PMID:
21357058
22.

Using genetically engineered kinases to screen for novel protein kinase substrates: phosphorylation of kinase-associated substrates.

Eblen ST, Kumar NV, Weber MJ.

CSH Protoc. 2007 Apr 1;2007:pdb.prot4638. doi: 10.1101/pdb.prot4638.

PMID:
21357057
23.

Using Genetically Engineered Kinases to Screen for Novel Protein Kinase Substrates: Generation of [{gamma}-32P]ATP Analog from ADP Analog.

Eblen ST, Kumar NV, Weber MJ.

CSH Protoc. 2007 Apr 1;2007:pdb.prot4637. doi: 10.1101/pdb.prot4637.

PMID:
21357056
24.

Using Genetically Engineered Kinases to Screen for Novel Protein Kinase Substrates: Identification of a Mutant Kinase/ATP Analog Pair.

Eblen ST, Kumar NV, Weber MJ.

CSH Protoc. 2007 Apr 1;2007:pdb.prot4636. doi: 10.1101/pdb.prot4636.

PMID:
21357055
25.

Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.

Gioeli D, Black BE, Gordon V, Spencer A, Kesler CT, Eblen ST, Paschal BM, Weber MJ.

Mol Endocrinol. 2006 Mar;20(3):503-15. Epub 2005 Nov 10.

PMID:
16282370
26.

MEK partner 1 (MP1): regulation of oligomerization in MAP kinase signaling.

Sharma C, Vomastek T, Tarcsafalvi A, Catling AD, Schaeffer HJ, Eblen ST, Weber MJ.

J Cell Biochem. 2005 Mar 1;94(4):708-19.

PMID:
15547943
27.

Identifying specific kinase substrates through engineered kinases and ATP analogs.

Kumar NV, Eblen ST, Weber MJ.

Methods. 2004 Apr;32(4):389-97.

PMID:
15003601
28.

Mitogen-activated protein kinase feedback phosphorylation regulates MEK1 complex formation and activation during cellular adhesion.

Eblen ST, Slack-Davis JK, Tarcsafalvi A, Parsons JT, Weber MJ, Catling AD.

Mol Cell Biol. 2004 Mar;24(6):2308-17.

29.

PAK1 phosphorylation of MEK1 regulates fibronectin-stimulated MAPK activation.

Slack-Davis JK, Eblen ST, Zecevic M, Boerner SA, Tarcsafalvi A, Diaz HB, Marshall MS, Weber MJ, Parsons JT, Catling AD.

J Cell Biol. 2003 Jul 21;162(2):281-91.

30.

Identification of novel ERK2 substrates through use of an engineered kinase and ATP analogs.

Eblen ST, Kumar NV, Shah K, Henderson MJ, Watts CK, Shokat KM, Weber MJ.

J Biol Chem. 2003 Apr 25;278(17):14926-35. Epub 2003 Feb 19.

31.
32.

Scaffold protein regulation of mitogen-activated protein kinase cascade.

Catling AD, Eblen ST, Schaeffer HJ, Weber MJ.

Methods Enzymol. 2001;332:368-87. No abstract available.

PMID:
11305112
33.
34.

c-Raf-mediated inhibition of epidermal growth factor-stimulated cell migration.

Slack JK, Catling AD, Eblen ST, Weber MJ, Parsons JT.

J Biol Chem. 1999 Sep 17;274(38):27177-84.

35.

Active MAP kinase in mitosis: localization at kinetochores and association with the motor protein CENP-E.

Zecevic M, Catling AD, Eblen ST, Renzi L, Hittle JC, Yen TJ, Gorbsky GJ, Weber MJ.

J Cell Biol. 1998 Sep 21;142(6):1547-58.

36.

MP1: a MEK binding partner that enhances enzymatic activation of the MAP kinase cascade.

Schaeffer HJ, Catling AD, Eblen ST, Collier LS, Krauss A, Weber MJ.

Science. 1998 Sep 11;281(5383):1668-71.

37.

Conditional binding to and cell cycle-regulated inhibition of cyclin-dependent kinase complexes by p27Kip1.

Eblen ST, Fautsch MP, Anders RA, Leof EB.

Cell Growth Differ. 1995 Aug;6(8):915-25.

38.

Differential regulation of p34cdc2 and p33cdk2 by transforming growth factor-beta 1 in murine mammary epithelial cells.

Fautsch MP, Eblen ST, Anders RA, Burnette RJ, Leof EB.

J Cell Biochem. 1995 Aug;58(4):517-26.

PMID:
7593274
39.

Dissociation of p34cdc2 complex formation from phosphorylation and histone H1 kinase activity.

Eblen ST, Fautsch MP, Burnette RJ, Snyder M, Leof EB.

Cancer Res. 1995 May 1;55(9):1994-2000.

40.

Cell cycle-dependent inhibition of p34cdc2 synthesis by transforming growth factor beta 1 in cycling epithelial cells.

Eblen ST, Fautsch MP, Burnette RJ, Joshi P, Leof EB.

Cell Growth Differ. 1994 Feb;5(2):109-16.

Supplemental Content

Loading ...
Support Center